On Thursday, Senator Bill Cassidy, M.D. (R-La.) announced the issuance of a new, extensive report from the U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee on the findings of an investigation into the abortion pill's manufacturers and distributors, including Danco Laboratories, GenBioPro, and Evita Solutions.

Key Takeaways:

• Senator Bill Cassidy has announced a new report on the investigation into the distribution and policing of the abortion pill in the U.S.

• What the HELP Committee's investigation found is disturbing, and includes information regarding abortion pill manufacturers' claim that they don't believe it is their responsibility to police prescribers or to de-certify them when prescribers violate the FDA's REMS requirements on the drug.

• However, according to the REMS agreement, these manufacturers are supposed to do this very thing.

The Details:

In a press release, Cassidy said the abortion pill report is the result of a "months-long investigation" into these companies, which Cassidy states are "fail[ing] to properly oversee the prescription and distribution of their products," adding that previous pro-abortion administrations "recklessly removed the Food and Drug Administration’s (FDA) Mifepristone Risk Evaluation and Mitigation Strategy (REMS) Program requirements for reporting non-fatal adverse events and in-person dispensing of chemical abortion drugs, among other important safeguards."

This, as Live Action News has reported, has led to the illusion of safety surrounding the abortion pill regimen (mifepristone and misoprostol), despite a lack of reporting and even systematic efforts to cover up adverse events by urging women to mislead medical personnel when seeking emergency care for abortion drug complications.

In addition, Cassidy noted something shocking in the press release (emphasis added):

Ending these [REMS] requirements has led to horrific instances of coerced abortions and the proliferation of chemical abortion drugs outside FDA-approved channels in ways that mislead pregnant women and seriously endanger their health and safety.

Despite these dangers, Danco, GenBioPro, and Evita do not take sufficient steps to ensure that their drugs are only available through REMS-compliant channels and that certified prescribers and pharmacies comply with the few remaining FDA requirements, especially when pills are sold online and without the in-person oversight of a medical professional....

In the course of the investigation, Danco and GenBioPro told the Committee that they have no role in ensuring that doctors and other health care providers who prescribe chemical abortion drugs maintain compliance with the FDA requirements, implying that the onus is on the prescribers to police themselves. Given the lack of oversight, there are concerns that these sponsors are disregarding the safety risks of chemical abortions and either overtly or tacitly allowing their products to be sold to bad actors who seek to exploit women for profit.

But, according to the FDA's REMS agreement modified as recently as September of 2025, it actually is their job to police prescribers:

The agreement states:

Mifepristone Sponsors must "Ensure that healthcare providers who prescribe their mifepristone are specially certified in accordance with the requirements described above and de-certify healthcare providers who do not maintain compliance with certification requirements" (emphasis added).

The report itself discusses:

• the history of the abortion pill's approval and "mechanism of action" in the U.S.

• how the REMS safety requirements came to be and what they are today

• background on the abortion pill's manufacturers and their locations

• the distributors, third-party administrators, and certified prescribers and pharmacies dispensing the abortion pill

• third-party websites selling the abortion pill

• adverse events and deaths associated with the abortion pill

... and more.

The Bottom Line:

It appears from this report that, in fact, the distribution of the abortion pill in the U.S. is essentially a "free-for-all" with little to no accountability from the abortion industry — and it is women and children who are paying the cost with their health and lives.

Note: Live Action News will publish an in-depth look at the report in a future article. Special thanks to Live Action Research Fellow Carole Novielli for her contribution to this article.